Helus Pharma announces Interim CEO Eric So will speak on a health innovation panel at the 29th Annual Milken Institute Global Conference on May 4, 2026, with live webcast on the investor relations website.
Key takeaways
Eric So, Helus Pharma’s Interim CEO, to appear on 'The Next Wave of Health Innovation' panel on May 4, 2026, at 2:30 p.m. PDT.
Conference held May 3-6, 2026, at The Beverly Hilton & Waldorf Astoria in Los Angeles.
Live panel and archived webcast available on Company’s investor relations Events & Presentations page.
Helus Pharma developing HLP003 in Phase 3 for major depressive disorder with FDA Breakthrough Therapy Designation.
HLP004 in Phase 2 for generalized anxiety disorder; extensive research portfolio of investigational NSAs.